HOME >> BIOLOGY >> NEWS
Birth defect gene identified

sure proper development. This suggests a potential therapy for embryos that are missing TGF-beta in the neural crest cells.

"This might be useful to try out some possible rescue experiments," Chai said.

Although Chai's current results apply only to mice, a paper last spring in Nature Genetics (Loeys et al., 2005) identified a handful of human families with inherited mutations in TGF-beta receptors and with a high incidence of craniofacial defects, including cleft palate and skull malformations.

If the signaling mechanism in mice were to carry over to humans, pharmaceutical researchers could start to investigate FGF as a potential supplement for pregnant women, analogous to folic acid for prevention of spina bifida.

Chai noted that the FGF supplements in mice restored normal cell growth only in the skull region.

"Using FGF signaling we can actually rescue the cell proliferation defect, but so far we have not been able to do the same thing in the palate," Chai said.

TGF-beta also appears to work through different mechanisms in other parts of the body, Chai added. This suggests that no single treatment can correct all birth defects related to TGF-beta.


'"/>

Contact: Carl Marziali
marziali@usc.edu
213-740-4751
University of Southern California
22-Dec-2005


Page: 1 2

Related biology news :

1. Birth rate, competition are major players in hominid extinctions
2. Birth defects: 8 million annually worldwide
3. Birth factors associated with risk for autism
4. Birthing a new model of aspirin therapy in preeclampsia
5. Penn researchers discover pathway that eliminates genetic defects in red blood cells
6. Monell researchers find metabolic defect in liver that can lead to obesity
7. Developer of new method for treating bone defects wins WPI Entrepreneurship Award
8. Genetic defect links respiratory disease and congenital heart disease
9. Erectile dysfunction in diabetes is due to selective defect in the brain
10. Transport interrupted -- Texas A&M biologists trace cause of early blindness to tissue defect
11. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Birth defect gene identified

(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: